Researchers found that a new topical treatment called QTORIN™ rapamycin significantly improves symptoms for people suffering from cutaneous venous malformations (VMs), a rare skin condition that can cause painful lesions and bleeding. In a recent clinical trial, all participants with bleeding at the start of the study reported a noticeable reduction in bleeding after 12 weeks of treatment. Additionally, every participant expressed satisfaction with the treatment, highlighting its potential to enhance quality of life for those affected.

This discovery is particularly relevant for the estimated 75,000 individuals in the U.S. living with cutaneous VMs. The treatment not only addresses the physical symptoms, such as bleeding and lesion appearance, but also aims to alleviate the emotional and social burdens that come with this condition. Many people with cutaneous VMs report pain, discomfort, and limitations in daily activities, which can impact their mental health and social interactions. The promising results from the trial suggest that QTORIN™ rapamycin could become a vital part of managing this condition.

The evidence comes from a Phase 2 clinical trial involving a small group of participants who applied the gel daily for 12 weeks. While the results are encouraging, they are still in the early stages of research, and further studies will be needed to confirm the long-term effectiveness and safety of this treatment. For now, the findings indicate a significant step forward for individuals struggling with the challenges of cutaneous VMs.

Source: globenewswire.com